Stock info Bavarian Nordic | Filter  Basic-Info

Bavarian Nordic

The past year gave good returns for Bavarian Nordic investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Bavarian Nordic, the stock lost around 32 percent. Over the period 2011-2016 the stock rose a massive 464,16 percent. Bavarian Nordic's revenues between 2011 and 2015 were quite stable and moved between 136,35 million euros and 136,75 million euros. Bavarian Nordic's net incomes between 2011 and 2015 were very volatile and moved between -36,11 million euros and 9,19 million euros.

The global pharmaceutical companies gained over the past 10 years on average 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The Danish company didn't pay out any dividends (in the past 5 years).

Healthy financed: not so much debt Bavarian Nordic

At the end of 2015 the pharmaceutical company's balance sheet equaled 266,56 million euros. The total debt of the pharmaceutical company was at the end of 2015 86,67 million euros, which equals around 32,51 percent of the total balance sheet. As per the end of 2015 Bavarian Nordic's price/earnings-ratio equaled 617. So investors paid for 1 stock 617 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the Danish stock can be seen as a growth stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 9,8 billion euros. At the end of 2015 the Danish company had around 27,8 million stocks listed on the exchanges.

At this page you find all Bavarian Nordic's financial reports. More information about Bavarian Nordic can be found it's website. .